AstraZeneca Concentrates Biologics At MedImmune, Ups R&D

 
• By Jessica Merrill

MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.

More from Archive

More from Pink Sheet